In the course of an external credit rating, CHEPLAPHARM is rated B/B1 - and thus stable future outlooks.
The first public capital markets transaction of CHEPLAPHARM Arzneimittel GmbH will be closed in the near future, following a diligent and intensive preparation. Prior to that, the initial rating process with the leading rating agencies S&P and Moody’s were successfully completed.
Based on individual discussions with the rating agencies, the management board had to answer numerous questions in detail. Furthermore, an extensive illustration of the business model and the business strategy was presented. With the now published rating results of B/B1 (both with stable outlook) CHEPLAPHARM’s management is feeling very content.
CFO Jens Rothstein commenting on the outcome: "The healthy debt structure is the main pillar of our business strategy, building the basis for the continuous growth of turnover and profit. So we are kind of pioneers in Mecklenburg-Western Pomerania among the family-owned companies and will continue to further develop our Capital Markets strategy."
Contact Investor Relations:
CHEPLAPHARM Arzneimittel GmbH | Jens Remmers | Ziegelhof 24 | 17489 Greifswald | investor-relations(at)cheplapharm.com